Related Experiment Videos
Small, dense low-density lipoprotein subclass pattern B: issues for the clinician
1Cholesterol, Genetics, and Heart Disease Institute, Berkeley HeartLab, Lawrence Berkeley National Laboratory, University of California, Berkeley, USA.
Insights
Coronary artery disease (CAD) is linked to lipoprotein metabolism disorders, especially Small, Dense Low-Density Lipoprotein Pattern B (Atherogenic Lipoprotein Profile). This condition accelerates CAD progression and is treatable with lifestyle changes and medication.
Area of Science:
- Cardiovascular Medicine
- Metabolic Disorders
- Lipidology
Background:
- Coronary artery disease (CAD) is significantly influenced by lipoprotein metabolism disorders.
- These disorders arise from a complex interplay between genetic predisposition and environmental factors.
Purpose of the Study:
- To highlight the role of Small, Dense Low-Density Lipoprotein Pattern B, also known as Atherogenic Lipoprotein Profile (ALP), in CAD.
- To emphasize ALP as an independent risk factor and predictor of disease progression in CAD patients.
Main Methods:
- Review of existing literature on lipoprotein metabolism and CAD.
- Analysis of the clinical significance of Atherogenic Lipoprotein Profile in patient subgroups.
Main Results:
- Atherogenic Lipoprotein Profile (ALP) is the most common lipoprotein disorder contributing to CAD.
- ALP is an independent risk factor for CAD.
- Patients with established CAD and ALP exhibit a twofold greater rate of arteriographic progression.
Conclusions:
- Effective management of CAD involves addressing lipoprotein metabolism disorders like ALP.
- Treatment strategies include lifestyle modifications and specific pharmacologic agents.
- Cost-effective treatments, primarily lifestyle interventions, are often the most impactful for ALP.
Abstract:
A large portion of coronary artery disease (CAD) can be attributed to disorders of lipoprotein metabolism. However, these disorders are a complex interaction of genetic susceptibility and environmental interaction. The most common disorder of lipoprotein metabolism contributing to CAD is the Small, Dense Low-Density Lipoprotein Pattern B disorder, also known as the Atherogenic Lipoprotein Profile (ALP), which consists of multiple metabolic disorders. This disorder is an independent risk factor for CAD and in patients with established CAD, identifies a subgroup with a twofold greater rate of arteriographic progression compared with CAD patients without this disorder. Treatment of the disorder is specific to lifestyle and some pharmacologic agents. The most effective treatments are often the least expensive.